AstraZeneca PLC (AZN)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
WOK
WORK Medical Technology Group LTD Ordinary Shares
$1.88
-2.59%
HEALTHCARE · Cap: $9.38M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 572456% more annual revenue ($61.37B vs $10.72M). AZN leads profitability with a 17.0% profit margin vs -41.9%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
WOK
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for WOK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
19.1% revenue growth
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -5.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : WOK
The strongest argument for WOK centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 19.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : WOK
The primary concerns for WOK are Altman Z-Score, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while WOK is a growth play — different risk/reward profiles.
WOK carries more volatility with a beta of 1.75 — expect wider price swings.
WOK is growing revenue faster at 19.1% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 35/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
WORK Medical Technology Group LTD Ordinary Shares
HEALTHCARE · MEDICAL DEVICES · USA
WORK Medical Technology Group Ltd is a pioneering player in the medical technology sector, dedicated to the advancement of healthcare through the research, development, and commercialization of innovative medical devices. The company's diverse portfolio is designed to tackle pressing challenges in global healthcare, underscoring its commitment to improving patient outcomes. With a strong emphasis on quality, innovation, and responsiveness to market demands, WORK is ideally positioned for sustainable growth, making it an attractive investment opportunity for institutional investors seeking exposure to transformational healthcare solutions in an evolving industry landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?